Bourla breaks down $6B bet for Chinese bispecific

Today’s Big News

Jun 10, 2025

FDA slaps clinical hold on multiple Gilead HIV combo therapy trials, shares fall

RFK Jr.'s HHS ousts entire roster of CDC vaccine expert committee

Pfizer CEO talks Chinese due diligence, ADC synergies to justify $6B bet on ‘fabulous’ bispecific

Scorpion spinout raises $177M to advance preclinical assets after 2 clinical programs sold to Pierre Fabre

Recursion lays off 20% of staff in wake of pipeline cutbacks

Activist investor demands Keros 'aggressively' cut costs just weeks after layoffs

Odyssey abandons IPO plans in latest sign of tough environment for biotech listings

300-plus NIH staffers demand director reverse funding and workforce cuts

Axsome plots new fibromyalgia trial after FDA refuses to review former Pfizer candidate

The Top Line Podcast: Don’t miss out on the newest episode. Listen now.

 

Featured

FDA slaps clinical hold on multiple Gilead HIV combo therapy trials, shares fall

By Ben Adams

Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid safety concerns.
 

Top Stories

RFK Jr.'s HHS ousts entire roster of CDC vaccine expert committee

By Eric Sagonowsky

The Department of Health and Human Services has removed all 17 sitting members of the CDC's Advisory Committee on Immunization Practices.

Pfizer CEO talks Chinese due diligence, ADC synergies to justify $6B bet on ‘fabulous’ bispecific

By Nick Paul Taylor

Pfizer CEO Albert Bourla has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing that his team went through individual scans and interviewed investigators to gain reassurance about the quality of the Chinese data.

Avoiding Costly Clinical Trial Delays Takes More Than Breaking Down Silos

Sponsored by WCG

When clinical trial steps are managed separately, the study suffers from compounded delays. Discover proven solutions from trusted industry experts.

Scorpion spinout raises $177M to advance preclinical assets after 2 clinical programs sold to Pierre Fabre

By Gabrielle Masson

After Eli Lilly snapped up Scorpion’s PI3Kα program earlier this year, the biotech is selling off its other two clinical assets and spinning out a new company to advance its three preclinical precision medicine candidates.

Why Puerto Rico is the smart choice for bioscience reshoring

Sponsored by Invest Puerto Rico

Global trade uncertainty and evolving tariff policies are shifting how bioscience companies view their supply chains.

Recursion lays off 20% of staff in wake of pipeline cutbacks

By James Waldron

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline.

Activist investor demands Keros 'aggressively' cut costs just weeks after layoffs

By James Waldron

Keros Therapeutics’ pledge to hand $375 million to shareholders has not been enough to appease activist investor demands to slash further costs just weeks after the biotech laid off staff.

Odyssey abandons IPO plans in latest sign of tough environment for biotech listings

By James Waldron

Odyssey Therapeutics has bailed on its long-awaited public listing in further evidence that the IPO window remains firmly shut for now.

300-plus NIH staffers demand director reverse funding and workforce cuts

By Darren Incorvaia

Hundreds of staffers at the National Institutes of Health (NIH) are urging agency Director Jay Bhattacharya, Ph.D., to reverse the drastic changes made within the last five months, including the termination of about $9.5 billion in federal research grants. Since President Donald Trump's inauguration, the NIH has ended 2,100 research grants worth around $9.5 billion and contracts worth $2.6 billion, the authors wrote in the June 9 Bethesda Declaration.

Axsome plots new fibromyalgia trial after FDA refuses to review former Pfizer candidate

By Darren Incorvaia

Axsome Therapeutics has hit a costly snag in its mission to bring esreboxetine to market for fibromyalgia. The FDA has refused to review the CNS specialist’s new drug application for the asset, with the agency determining that one of the two trials in the filing was not up to snuff.

National Resilience will close 6 of its 10 plants and carry on as streamlined CDMO

By Kevin Dunleavy

National Resilience is consolidating its CDMO business, closing six of its plants and continuing to operate as a streamlined company at four sites, including its anchor facility in Cincinnati.

UnitedHealth weighs bids for Latin America operations: Reuters

By Heather Landi

The company has four nonbinding bids for its Banmédica subsidiary, which operates in Colombia and Chile, for about $1 billion, Reuters reported, citing two people with direct knowledge of the matter.

Merck scores FDA nod for Enflonsia, setting up RSV market battle vs. Sanofi and AstraZeneca's Beyfortus

By Kevin Dunleavy

The FDA has blessed Merck’s clesrovimab to protect against lower respiratory tract disease related to respiratory syncytial virus in newborns and infants. The monoclonal antibody, which will be known commercially as Enflonsia, will challenge Sanofi and AstraZeneca’s blockbuster Beyfortus.
 
Fierce podcasts

Don’t miss an episode

Inside ASCO 2025: Big data drops and a towering campaign

This week on "The Top Line," the Fierce team reports from ASCO, highlighting key takeaways on clinical data, standout campaigns and buzz from the exhibit floor.

What’s next for tech-enabled home care? A look at the policy road ahead

Biopharma briefing: Q1 trends, gene therapy updates and ASCO preview

 

Resources

Whitepaper

Building Peak Performance Go-to-Market Operations

We analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance.

Presented by Blue Matter, strategic consultants in the life sciences

 

Upcoming Fierce Events

8-11
Sep
Fierce Pharma Week
Philadelphia, PA
10
Sep
Fierce Pharma Marketing Awards
Philadelphia, PA
7-9
Oct
Fierce Biotech Week
Boston, MA
12-13
Nov
Diversity, Equity & Inclusion Forum
Free Virtual Event
20
Nov
Fierce 50 Awards Gala
The Lighthouse at Pier 61 in New York City

View all events